PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma.

PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma. Cancer Chemother Pharmacol. 2022 05; 89(5):643-653.

View in: PubMed